Reactions 1704, p353 - 2 Jun 2018 Renal toxicity: case report An 8-month-old male infant developed renal toxicity during treatment with tacrolimus [route, dosage, indication and duration of treatment to reaction onset not stated]. The infant, who had a progressive cholestatic liver cirrhosis, was scheduled for liver transplantation. He receiving treatment with tacrolimus at that time. During the operation, he required continuous veno-venous haemofiltration (CVVH) for volume management. He developed renal toxicity secondary to tacrolimus, due to which CVVH was continued even after the transplantation. The trough level of tacrolimus trasiently increased to 22 ng/mL. Subsequently, his renal function recovered and CVVH was stopped. Author comment: "Postoperatively, the patient continued to be dependent on [continuous venovenous hemofiltration], mainly due to tacrolimus renal toxicity (the trough of tacrolimus transiently rose to 22 ng/mL).""On top of his cardiac condition, his renal function was compromised due to both hepatorenal syndrome and tacrolimus toxicity." Yamada Y, et al. Successful management of living donor liver transplantation for biliary atresia with single ventricle physiology-from peri-transplant through total cavopulmonary connection: A case report. Pediatric Transplantation 22: e13118, No. 3, May 2018. Available from: URL: http://doi.org/10.1111/petr.13118 - Japan 803323230 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud